FUJIFILM Diosynth Biotechnologies partners with SHL Medical to expand its autoinjector services; the partnership aims to streamline production, enhance efficiency, and increase manufacturing capacity to 30 million units per year starting from 2025

Sample article from our Health Care Sector

HILLERØD, Denmark and ZUG, Switzerland , January 8, 2024 (press release) –

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies and oncolytic viruses today announced that it will expand its finished goods autoinjector services through a non-exclusive strategic partnership agreement with SHL Medical (SHL), a world-leading solutions provider of advanced drug delivery systems. The partnership, part of SHL’s Alliance Management Program, aims to streamline processes and enhance efficiency for pharmaceutical and biotech companies offering self-injection device finished goods services primarily with SHL’s flagship platform Molly®. FUJIFILM Diosynth Biotechnologies will offer pre-validated final assembly services for Molly autoinjectors for its global customers with increased capacity of up to 30 million units per year beginning early 2025. 

Autoinjectors deliver medicines in a patient-centric manner using specifically designed devices that administer medications through a subcutaneous or intramuscular route. Pre-filled injectors have a projected growth rate of approximately 10% per year between now and 2030  due to the rise in self-administration especially for chronic diseases including diabetes and obesity. Autoinjector medicines can improve patient safety by reducing potential drug contamination and offer ease of use and convenience for patients who are eligible for self-administration.  

“Partnering with SHL will expand FUJIFILM Diosynth Biotechnologies’ ability to offer top-quality, high-speed final assembly of autoinjectors to customers seeking our CDMO services,” said Kenneth Bilenberg, chief operating officer, and executive vice president, large-scale business unit, FUJIFILM Diosynth Biotechnologies. “Having access to SHL’s full network of solutions and services will enhance our ability to support our customers in improving patient access using autoinjector medicines.”  

The strategic partnership will allow SHL to recommend FUJIFILM Diosynth Biotechnologies for final assembly of the Molly autoinjector to customers seeking CDMO services, leading to faster development, streamlined communications, reduced supply chain risks, and a more sustainable manufacturing footprint.  
“Expanding our finished goods services at our site in Hillerød, Denmark underscores our commitment to fulfill the needs of our customers,” said Christian Houborg, site head, FUJIFILM Diosynth Biotechnologies, Hillerød, Denmark. “When current drug product expansions and automation projects are complete, our increased capacity and capabilities will enable us to improve patient access to life-impacting medicines, saving our customers time, money, and reducing their products’ carbon footprint by providing drug substance, drug product and finished goods services from our Denmark site.”  

“A number of customers with manufacturing infrastructure in Europe have sought our guidance in recommending a trusted final assembly partner that can support their commitment to a localized supply chain,” said SHL Medical Chief Growth Officer Markus Puusepp. “It is with great pleasure that we will now be able to recommend FUJIFILM Diosynth Biotechnologies to them with the full confidence that the collaboration will further support their needs for faster timelines to clinic and to market.”

About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner for the development and manufacture of biologics, vaccines, cell and gene therapies, and oncolytic viruses. The company operates a global network with major locations in the United States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacture of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, go to: www.fujifilmdiosynth.com.

About SHL Medical
As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  
In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. 
Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.
For additional information, visit www.shl-medical.com.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.